{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:35:25Z","timestamp":1773660925555,"version":"3.50.1"},"reference-count":15,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Parkinson's disease (PD) is a systemic disease with motor and non-motor deficits. We recruited three patients with newly diagnosed PD. They were not under anti-Parkinson's therapy. Plasmatic thiamine was within healthy reference range. We performed the Unified Parkinson's Disease Rating Scale (UPDRS) and started a parenteral therapy with high doses of thiamine. The therapy led to a considerable improvement in the motor part of the UPDRS ranging from 31.3% to 77.3%. From this clinical observation, it is reasonable to infer that a focal, severe thiamine deficiency due to a dysfunction of thiamine metabolism could cause a selective neuronal damage in the centres that are typically hit in this disease. Injection of high doses of thiamine was effective in reversing the symptoms, suggesting that the abnormalities in thiamine-dependent processes could be overcome by diffusion-mediated transport at supranormal thiamine concentrations.<\/jats:p>","DOI":"10.1136\/bcr-2013-009289","type":"journal-article","created":{"date-parts":[[2013,8,28]],"date-time":"2013-08-28T11:35:22Z","timestamp":1377689722000},"page":"bcr2013009289","source":"Crossref","is-referenced-by-count":29,"title":["High-dose thiamine as initial treatment for Parkinson's disease"],"prefix":"10.1136","volume":"2013","author":[{"given":"Antonio","family":"Costantini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Immacolata","family":"Pala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Compagnoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Colangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,8,28]]},"reference":[{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00702-010-0482-8","article-title":"Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease","volume":"2013","author":"Ferrer","year":"2011","journal-title":"J Neural Transm"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.2","first-page":"229","article-title":"Levodopa in the treatment of Parkinson's disease: an old drug still going strong","volume":"2013","author":"Poewe","year":"2010","journal-title":"Clin Interv Aging"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.3","doi-asserted-by":"crossref","unstructured":"Costantini A Pala MI Colangeli M . Thiamine and spinocerebellar ataxia type 2. BMJ Case Rep Published Online: 10 Jan 2013. doi:10.1136\/bcr-2012-007302","DOI":"10.1136\/bcr-2012-007302"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.parkreldis.2008.09.005","article-title":"Intrafamilial variability of Parkinson's phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions","volume":"2013","author":"Socal","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2012.02.008","article-title":"Thiamine and Parkinson's disease","volume":"2013","author":"Lu'o'ng","year":"2012","journal-title":"J Neurol Sci"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.6","first-page":"211","article-title":"The beneficial role of thiamine in Parkinson's disease: preliminary report","volume":"2013","author":"Luong","year":"2012","journal-title":"J Neurol Res"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.7","unstructured":"Herndon R . The handbook of neurologic rating scales. 2nd edn. New York: Demos Medical Publishing, 2006."},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease","volume":"2013","author":"Gibb","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.9","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/mds.25008","article-title":"Reversible generalized dystonia and encephalopathy from thiamine transporter 2 deficiency","volume":"2013","author":"Serrano","year":"2012","journal-title":"Mov Disord"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ecam\/nek009","article-title":"A review of the biochemistry, metabolism and clinical benefits of thiamin (e) and its derivatives","volume":"2013","author":"Lonsdale","year":"2006","journal-title":"Evid Based Complement Alternat Med"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.11","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMc0809100","article-title":"Mutation in a thiamine-transporter gene and Wernicke's-like encephalopathy","volume":"2013","author":"Kono","year":"2009","journal-title":"N Engl J Med"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1089\/ars.2007.1766","article-title":"Thiamine-dependent processes and treatment strategies in neurodegeneration","volume":"2013","author":"Gibson","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1089\/ars.2011.4200","article-title":"Mitochondrial dysfunction in genetic animal models of Parkinson's disease","volume":"2013","author":"Trancikova","year":"2012","journal-title":"Antioxid Redox Signal"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.neuint.2010.11.019","article-title":"Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism","volume":"2013","author":"Jhala","year":"2011","journal-title":"Neurochem Int"},{"key":"2025042709091086000_2013.aug28_1.bcr2013009289.15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-12-4","article-title":"Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects","volume":"2013","author":"Smithline","year":"2012","journal-title":"BMC Clin Pharmacol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2013-009289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T16:09:21Z","timestamp":1745770161000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2013-009289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,28]]},"references-count":15,"alternative-id":["10.1136\/bcr-2013-009289"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2013-009289","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,28]]}}}